Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Rapport Therapeutics Logo
Rapport Therapeutics Growth Score
60
CB Rank
7103
Heat Score
25
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Founded
obfuscation
PublicPost-IPO Equity Boston, Massachusetts, United States51-100 www.rapportrx.com
Biotechnology
Health Care
Life Science
Medical
Neuroscience
Precision Medicine
Overview

Rapport Therapeutics
Total Funding
obfuscation
Growth Score
60
Heat Score
25

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score60
-2 pts
in past quarter
Heat Score 25
21 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Rapport Therapeutics

CB Rank
7103
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Founded
obfuscation
PublicPost-IPO Equity Boston, Massachusetts, United States51-100 www.rapportrx.com
Biotechnology
Health Care
Life Science
Medical
Neuroscience
Precision Medicine

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Series B
OBF
in
obfuscation
Series A
OBF
in
obfuscation

Key People

Details

Legal Name RAPPORT THERAPEUTICS, Inc.
Also Known As Precision Neuroscience NewCo
Operating Status Active
Stock Symbol  NASDAQ:RAPP
Company Type For Profit
Founders  David Bredt, Steven Paul
About the Company
Rapport Therapeutics operates as a clinical-stage biotechnology company, that discovers and develops precision medicines for neurological disorders. Rapport Therapeutics describes relationships that are defined by understanding, communication, teamwork, and trust.
Phone Number (857) 321-8020
Predictions & Insights

Growth Insight

See this Growth Insight
Rapport Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

RAP-219
A selective negative allosteric modulator targeting the AMPA receptor-associated protein TARPγ8, developed for epilepsy treatment.
RTX-1738
A small molecule candidate exhibiting analgesic activity across various preclinical pain models for neurological disorders.

Research & Development

Rapport Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Rapport Therapeutics Logo
Post-IPO Equity - Rapport Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 4 Board Members and Advisors 7 Contacts 33

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,800
80.01%
 in past month

IT Spend

$1MThis year, Rapport Therapeutics is projected to spend $1M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Warner Bros. Discovery Logo
Warner Bros. Discovery
90
Nimble Logo
Nimble
87
Stock Replenishment Logo
Stock Replenishment
85

Active Website Tech Count

40Rapport Therapeutics is actively using 40 technologies for its website, according to BuiltWith. These include HSTS, Apple Mobile Web Clips Icon, and  Google Tag Manager.

Total IP

6The intellectual property of Rapport Therapeutics includes 6 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Rapport Therapeutics's headquarters? Rapport Therapeutics is located in Boston, Massachusetts, United States.Who invested in Rapport Therapeutics? Rapport Therapeutics has 11 investors including Sofinnova Investments and  T. Rowe Price.When was the last funding round for Rapport Therapeutics? Rapport Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Rapport Therapeutics's competitors? Alternatives and possible competitors to Rapport Therapeutics may include Alto Neuroscience, Draig Therapeutics, and  Leal Therapeutics.How much funding has Rapport Therapeutics raised to date? Rapport Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|